SEARCH

SEARCH BY CITATION

References

  • 1
    Roubinian J, Talal N, Siiteri PK, Sadakian JA: Sex hormone modulation of autoimmunity in NZB/NZW mice. Arthritis Rheum 22: 11621169, 1979
  • 2
    Steinberg AD, Melez KA, Raveche ES, Reeves JP, Boegel WA, Smathers PA, Taurog JD, Weinlein L, Duvic M: Approach to the study of the role of sex hormones in autoimmunity. Arthritis Rheum 22: 11701176, 1979
  • 3
    Carlsten H, Nilsson N, Jonsson R, Backman K, Holmdahl R, Tarkowski A: Estrogen accelerates immune complex glomerulonephritis but ameliorates T cell-mediated vasculitis and sialoadenitis in autoimmune MRL lpr/lpr mice. Cell Immunol 144: 190202, 1992
  • 4
    Petri M, Howard D, Repke J: Frequency of lupus flare in pregnancy: the Hopkins Lupus Pregnancy Center experience. Arthritis Rheum 34: 15381545, 1991
  • 5
    Zulman JI, Talal N, Hoffman GS, Epstein WV: Problems associated with the management of pregnancies in patients with systemic lupus erythematosus. J Rheumatol 7: 3749, 1980
  • 6
    Lockshin MD: Pregnancy does not cause systemic lupus erythematosus to worsen. Arthritis Rheum 32: 665670, 1989
  • 7
    Lockshin MD, Reinitz E, Druzin ML, Murrman M, Estes D: Lupus pregnancy. I. Case-control prospective study demonstrating absence of lupus exacerbation during or after pregnancy. Am J Med 77: 893898, 1984
  • 8
    Urowitz MB, Gladman DD, Farewell VT, Stewart J, McDonald J: Lupus and pregnancy studies. Arthritis Rheum 36: 13921397, 1993
  • 9
    Jara LJ, Lavalle C, Espinoza LR: Does prolactin have a role in the pathogenesis of systemic lupus erythematosus? J Rheumatol 19: 13331336, 1992
  • 10
    Jara-Quezada L, Graef A, Lavalle C: Prolactin and gonadal hormones during pregnancy in systemic lupus erythematosus. J Rheumatol 18: 349353, 1991
  • 11
    McMurray RW, Keisler D, Izui S, Walker SE: Hyperprolactinemia in male NZB/NZW (B/W) F1 mice: accelerated autoimmune disease with normal circulating testosterone. Clin Immunol Immunopathol 71: 338343, 1994
  • 12
    Petri M, Chan D, Magder L, Goldman D: Longitudinal analysis of prolactin and disease activity in SLE pregnancy (abstract). Arthritis Rheum 38 (Suppl 9): S220, 1995
  • 13
    Lahita RG, Bucala R, Bradlow HL, Fishman J: Determination of 16 alpha-hydroxyestrone by radioimmunoassay in systemic lupus erythematosus. Arthritis Rheum 28: 11221127, 1985
  • 14
    Tarzy BJ, Garcia CR, Wallach EE, Zweiman B, Myers AR: Rheumatic disease, abnormal serology and oral contraceptives. Lancet 2: 501503, 1972
  • 15
    Sanchez-Guerrero J, Liang MH, Karlson EW, Hunter DJ, Colditz GA: Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. Ann Intern Med 122: 430433, 1995
  • 16
    Jungers P, Dougados M, Pélissier C, Kuttenn F, Tron F, Lesavre P, Bach J-F: Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus. Arthritis Rheum 25: 618623, 1982
  • 17
    Julkunen HA: Oral contraceptives in systemic lupus erythematosus: side-effects and influence on the activity of SLE. Scand J Rheumatol 20: 427433, 1991
  • 18
    Buyon JP, Kalunian KC, Skovron ML, Petri M, Lahita R, Merrill J, Sammaritano L, Yung C, Licciardi F, Belmont HM, Hahn BH: Can women with systemic lupus erythematosus safely use exogenous estrogens? J Clin Rheumatol 1: 205212, 1995
  • 19
    Oral contraceptives, venous thrombosis, and varicose veins: Royal College of General Practitioners' Oral Contraception Study. J R Coll Gen Pract 28: 393399, 1978
  • 20
    Vessey MP: Steroid contraception, venous thromboembolism, and stroke: data from countries other than the United States. In, Risks, Benefits, and Controversies in Fertility Control. Edited by JJSciarra, GIZatuchni, JJSpeidel. Hagerstown, MD, Harper & Row, 1978
  • 21
    Inman WHW, Vessey MP, Westerholm B, Engelund A: Thromboembolic disease and the steroidal content of oral contraceptives: a report to the Committee on Safety of Drugs. BMJ 2: 203209, 1970
  • 22
    Meade TW, Greenberg G, Thompson SG: Progestagens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-μg oestrogen preparations. BMJ 280: 11571161, 1980
  • 23
    Stadel BV: Oral contraceptives and cardiovascular disease (first of two parts). N Engl J Med 305: 612618, 1981
  • 24
    Vessey MP, Mant D, Smith A, Yeates D: Oral contraceptives and venous thromboembolism: findings in a large prospective study (abstract). BMJ 292: 526, 1986
  • 25
    Kay CR: Progestogens and arterial disease: evidence from the Royal College of General Practitioners' study. Am J Obstet Gynecol 142: 762765, 1982
  • 26
    Thorogood M, Vessey MP: Trends in use of oral contraceptives in Britain. Br J Fam Plann 16: 4153, 1990
  • 27
    Gerstmann BB, Piper JM, Freiman JP, Tomita DK, Kennedy DL, Ferguson WJ, Bennett RC: Oral contraceptive oestrogen and progestin potencies and the incidence of deep venous thromboembolism. Int J Epidemiol 19: 931936, 1990
  • 28
    Wells PS, Hirsh J, Anderson DR, Lensing AW, Foster G, Kearon C, Weitz J, D'Ovidio R, Cogo A, Prandoni P: Accuracy of clinical assessment of deep-vein thrombosis. Lancet 345: 13261330, 1995
  • 29
    Poulose KP, Reba RC, Gilday DL, Deland FH, Wagner HN: Diagnosis of pulmonary embolism: a correlative study of the clinical, scan, and angiographic findings. BMJ 3: 6771, 1970
  • 30
    Singh K, Viegas OA, Loke D, Ratnam SS: Effect of Norplant-2 rods on liver, lipid and carbohydrate metabolism. Contraception 45: 463472, 1992
  • 31
    Singh K, Viegas OA, Loke DF, Ratnam SS: Effect of Norplant implants on liver, lipid and carbohydrate metabolism. Contraception 45: 141153, 1992
  • 32
    Singh K, Viegas OA, Loke DF, Ratnam SS: Evaluation of liver function and lipid metabolism following Norplant-2 rods removal. Adv Contracept 9: 233239, 1993
  • 33
    Rabe T, Thuro HC, Goebel K, Borchardt C, Grunwald K, Runnebaum B: Lipid metabolism in Norplant-2 users—a two-year follow-up study: total cholesterol, triglycerides, lipoproteins and apolipoproteins. Contraception 45: 2137, 1992
  • 34
    Otubu JA, Towobola OA, Aisien AO, Ogunkeye OO: Effects of Norplant contraceptive subdermal implants on serum lipids and lipoproteins. Contraception 47: 149159, 1993
  • 35
    Samsioe G: Coagulation and anticoagulation effects of contraceptive steroids. Am J Obstet Gynecol 170: 15231527, 1994
  • 36
    World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception: A multinational case-control study of cardiovascular disease and steroid hormone contraceptives: description and validation of methods. J Clin Epidemiol 48: 15131547, 1995
  • 37
    Robinson GE: Low-dose combined oral contraceptives. Br J Obstet Gynaecol 101: 10361042, 1994
  • 38
    Speroff L, DeCherney A: Evaluation of a new generation of oral contraceptives. Obstet Gynecol 81: 10341047, 1993
  • 39
    Watt AH: Oral contraceptives and venous thromboembolism (letter). Lancet 346: 1430, 1995
  • 40
    Nicolaides AN, Irving D: Clinical factors and the risk of deep venous thrombosis. In, Thromboembolism. Edited by ANNicolaides. London, MTP, 1995
  • 41
    World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception: Venous thromboembolic disease and combined oral contraceptives: results of an international multicentre case-control study. Lancet 346: 15751582, 1995
  • 42
    Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C: Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346: 15891593, 1995
  • 43
    Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, Macrae KD: Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ 312: 8388, 1996
  • 44
    Lewis MA, Spitzer WO, Heinemann LAJ, Macrae KD, Bruppacher R, Thorogood M: Third generation oral contraceptives a risk of myocardial infarction: an international case-control study. BMJ 312: 8890, 1996
  • 45
    Poulter NR, Farley TMM, Chang CL, Marmot MG, Meirik O: Safety of combined oral contraceptive pills (letter). Lancet 347: 547, 1996
  • 46
    Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Büller HR, Vandenbroucke JP: Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 346: 15931596, 1995
  • 47
    Villa P, Aznar J, Mira Y, Fernández MA, Vayá A: Third-generation oral contraceptives and low free protein S as a risk for venous thrombosis (letter). Lancet 347: 397, 1996
  • 48
    Meade TW: Recent developments on the association between oral contraceptives and cardiovascular disease. Adv Drug React Acute Poisoning Rev 1: 243254, 1982
  • 49
    Royal College of General Practitioners: Further analysis of mortality in oral contraceptive users. Lancet 1: 541546, 1981
  • 50
    Girard M: Thromboembolism and the combined oral contraceptive (letter). Lancet 346: 317, 1995
  • 51
    Todd GR, McAteer EJ, Jack CM, Maire M, Roberts SD, Buchanan KD: Pulmonary hypertension, systemic lupus erythematosus, and the contraceptive pill. Ann Rheum Dis 44: 266267, 1985
  • 52
    Miller MH: Pulmonary hypertension, systemic lupus erythematosus, and the contraceptive pill: another report. Ann Rheum Dis 46: 159161, 1987
  • 53
    Sandoval J, Amigo M-C, Barragan R, Izaguirre R, Reyes PA, Martinez-Guerra ML, Palomar A, Gomez A, Garcia-Torres R: Primary antiphospholipid syndrome presenting as chronic thromboembolic pulmonary hypertension: treatment with thromboendarterectomy. J Rheumatol 23: 772775, 1996
  • 54
    Asherson RA, Cervera R: Antiphospholipid antibodies and the lung. J Rheumatol 22: 6266, 1995
  • 55
    Julkunen HA, Kaaja R, Friman C: Contraceptive practice in women with systemic lupus erythematosus. Br J Rheumatol 32: 227230, 1993
  • 56
    Asherson RA, Harris EN, Hughes GRV, Farquarson RG: Complications of oral contraceptives and antiphospholipid antibodies (letter). Arthritis Rheum 31: 575576, 1988
  • 57
    Bruneau C, Intrator L, Sobel A, Beaumont V, Billecocq A: Antibodies to cardiolipin and vascular complications in women taking oral contraceptives (letter). Arthritis Rheum 29: 1294, 1986
  • 58
    Petri M, Hellmann D, Hochberg M, Meyerhoff J, Bell W, Goldman D: Arterial thrombotic events in SLE: the Baltimore Lupus Cohort study (abstract). Arthritis Rheum 37 (Suppl 9): S297, 1994
  • 59
    Petri M, Haffer S, Goldman D: Bimodal pattern of thrombosis in SLE (abstract). Arthritis Rheum 37 (Suppl 9): S323, 1994
  • 60
    Petitti DB, Sidney S, Bernstein A, Wolf S, Quesenberry C, Ziel HK: Stroke in users of low-dose oral contraceptives. N Engl J Med 335: 815, 1996
  • 61
    National Center for Health Statistics Advance Data. Washington, DC, NCHS, Vol. 182, 1990
  • 62
    Mintz G, Gutierrez C, Deleze M, Rodriquez E: Contraception with progestagens in systemic lupus erythematosus. Contraception 30: 2938, 1984
  • 63
    Julkunen H, Kaaja R, Jouhikainen T, Teppo AM, Friman C: Malignant hypertension and antiphospholipid antibodies as presenting features of SLE in a young woman using oral contraceptives. Br J Rheumatol 30: 471472, 1991
  • 64
    Yell JA, Burge SM: The effect of hormonal changes on cutaneous disease in lupus erythematosus. Br J Dermatol 129: 1822, 1993
  • 65
    Steinberg AD, Steinberg BJ: Lupus disease activity associated with menstrual cycle (letter). J Rheumatol 12: 816817, 1985
  • 66
    Petri M, Lim GS, Goldman D: Menstruation and systemic lupus erythematosus (abstract). Arthritis Rheum 35 (Suppl 9): S241, 1992
  • 67
    Pando JA, Gourley MF, Wilder RL, Crofford LJ: Hormonal supplementation as treatment for cyclical rashes in patients with systemic lupus erythematosus. J Rheumatol 22: 21592162, 1995
  • 68
    Lundström V, Green K, Wiqvist N: Prostaglandins, indomethacin and dysmenorrhea. Prostaglandins 11: 893904, 1976
  • 69
    Ekström P, Åkerlund M, Forsling M, Kindahl H, Laudanski T, Mrugacz G: Stimulation of vasopressin release in women with primary dysmenorrhoea and after oral contraceptive treatment—effect on uterine contractility. Br J Obstet Gynaecol 99: 680684, 1992
  • 70
    Grimes DA, Godwin AJ, Rubin A, Smith A, Lacarra M: Ovulation and follicular development associated with three low-dose oral contraceptives: a randomized controlled trial. Obstet Gynecol 83: 529533, 1994
  • 71
    Petri M: Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: an update. Arthritis Care Res 8: 137145, 1995
  • 72
    Lindsay R: The effect of sex steroids on the skeleton in premenopausal women. Am J Obstet Gynecol 166: 19931996, 1992
  • 73
    Boumpas DT, Austin HA III, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, Balow JE: Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340: 741745, 1992
  • 74
    McCune WJ, Golbus J, Zeldes W, Bohlke P, Dunne R, Fox DA: Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 318: 14231431, 1988
  • 75
    Wang CL, Wang F, Bosco JJ: Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus. Lupus 4: 1114, 1995
  • 76
    Boumpas DT, Austin HA III, Vaughan EM, Yarboro CH, Klippel JH, Balow JE: Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 119: 366369, 1993
  • 77
    Chapman RM, Sutcliffe SB: Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin's disease. Blood 58: 849851, 1981
  • 78
    Glode LM, Robinson J, Gould SF: Protection from cyclophosphamide-induced testicular damage with an analogue of gonadotropin-releasing hormone. Lancet 1: 11321134, 1981
  • 79
    Nseyo UO, Huben RP, Klioze SS, Pontes JE: Protection of germinal epithelium with luteinizing hormone-releasing hormone analogue. J Urol 34: 187190, 1985
  • 80
    Ataya KM, McKanna JA, Weintraub AM, Clark MR, LeMaire WJ: A luteinizing hormone-releasing hormone agonist for the prevention of chemotherapy-induced ovarian follicular loss in rats. Cancer Res 45: 36513656, 1985
  • 81
    Chatterjee R, Mills W, Katz M, McGarrigle HH, Goldstone AH: Induction of ovarian function by using short-term human meno-pausal gonadotropin in patients with ovarian failure following cytotoxic chemotherapy for hematological malignancy. Leuk Lymphoma 10: 383386, 1993
  • 82
    Petri M: Gender-based differences in autoimmunity and autoimmune disease. J Wom Health 4: 433436, 1995
  • 83
    Travers RL, Hughes GRV: Oral contraceptive therapy and systemic lupus erythematosus. J Rheumatol 5: 448451, 1978
  • 84
    Garovich M, Agudelo C, Pisko E: Oral contraceptives and systemic lupus erythematosus. Arthritis Rheum 23: 13961398, 1980
  • 85
    Pimstone B: Systemic lupus erythematosus exacerbated by oral contraceptives. South Afr J Obstet Gynaecol 3: 6263, 1966
  • 86
    Hadida M, Sayag J: Lupus érythémateux subanu apparu après une cure du Norfutin chez une malade atteinte de lupus érythémateux chronique. Bull Soc Fr Dermatol Syph 74: 616621, 1968
  • 87
    Chapel TA, Burns RE: Oral contraceptives and exacerbation of lupus erythematosus. Am J Obstet Gynecol 110: 366369, 1971
  • 88
    Laugier P, Orusco P, Chatelanat F, Humair L, Posternak S: Lupus érythémateux disseminé induit par estrogénes. Bull Soc Fr Dermatol Syph 78: 623628, 1971